SCHEMBL4676178

SCHEMBL4676178

O=C(O)/C(O)=C/C(=O)c1ccsc1Cc1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.44
HCAR2 Q8TDS4 2/20 0.39
RAB9A P51151 2/20 0.38
MAPK1 P28482 1/20 0.38
FEN1 P39748 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
SLC1A1 P43005 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
NR4A2 P43354 1/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676180 1.00 MAPK8 (0.44) MAPK8HCAR2RAB9AMAPK1FEN1
SCHEMBL4673929 0.87 PTPN1 (0.38) MAPK8RAB9AMAPK1GPR52MEN1
SCHEMBL4673936 0.87 PTPN1 (0.38) MAPK8RAB9AMAPK1GPR52MEN1
SCHEMBL4674868 0.86 MAPK8 (0.39) MAPK8RAB9AMEN1KMT2AL3MBTL1
SCHEMBL4674863 0.86 MAPK8 (0.39) MAPK8RAB9AMEN1KMT2AL3MBTL1
SCHEMBL4673784 0.81 HCAR2 (0.38) MAPK8HCAR2RAB9AMAPK1FEN1
SCHEMBL4673789 0.81 HCAR2 (0.38) MAPK8HCAR2RAB9AMAPK1FEN1
SCHEMBL7828506 0.80 MAPK8 (0.46) MAPK8HCAR2RAB9AMAPK1FEN1
SCHEMBL4674987 0.79 HPGD (0.41) MAPK8RAB9AFEN1MEN1KMT2A
SCHEMBL4674980 0.79 HPGD (0.41) MAPK8RAB9AFEN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MAPK8 2178/4885HCAR2 276/4885RAB9A 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.